Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Jefferies MedTech & Biotech Virtual Summit 2022
20 slides from Proteomics International Laboratories's conference presentation, May 26, 2022
Slide 1: ASX Release: Investor Presentation
ASX Release 26 May 2022 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at the Jefferies MedTech & Biotech virtual summit being held
Slide 2: Jefferies MedTech & Biotech Virtual Summit Investor Presentation
ASX: PIQ Proteomics International LABORATORIES LTD Jefferies MedTech & Biotech Virtual Summit Investor Presentation 26 May 2022 Dr. Richard Lipscombe Managing Director
Slide 3: Disclaimer
Disclaimer ASX: PIQ ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associ
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ ASX:PIQ A medical technology company at the forefront of Corporate Snapshot – 23/05/2022 precision medicine and predictive diagnostics ASX code PIQ Share Price A$1.01 Diagnostics Shares on issue (+8.4m options) 106m PromarkerD Market Capitalisation
Slide 5: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), CA, MAICD, Non-Executive Chair ASX:PIQ Seasoned finance professional with over 30 years’ experience providing South & corporate advice to Boards of public and private companies. He was Co-Founder and MD of Torr
Slide 6: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 5
Slide 7: A new blood test for predicting diabetic kidney disease
ASX: PIQ ASX:PIQ A new blood test for predicting diabetic kidney disease 6
Slide 8: Problem & Solution
Problem & Solution ASX: PIQ ASX:PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the Roadblock onset of diabetic kidney disease The Problem • If unchecke
Slide 9: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX: PIQ The PromarkerD predictive test is poised to roll-out in markets globally ASX:PIQ Enormous Market ✓ 537m adults have diabetes globally: 1-in-3 currently have diabetic kidney disease (DKD) Peer reviewed publications – Clinical & analytical validity proven (Sensitiv
Slide 10: PromarkerD – Simple Integration & Utilisation
PromarkerD – Simple Integration & Utilisation ASX: PIQ ASX:PIQ Blood sample drawn Biomarkers analysed Results analysed by Results and intervention PromarkerD Hub software plan delivered Sample is drawn at clinic Laboratory uses a standard Cloud based algorithm, the Clinician delivers results or path
Slide 11: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention How PromarkerDTM results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Annually •
Slide 12: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ PromarkerD significantly enhances diabetic kidney disease diagnosis and management ASX:PIQ Peer reviewed PromarkerD tested on over 5,000 patients in 4-year clinical studies PromarkerD predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney
Slide 13: PromarkerD Market Opportunity
PromarkerD Market Opportunity ASX: PIQ ASX:PIQ 45% Diabetes incidence and Patent portfolio undiagnosed Country Patent/Application No Patent Status No. Diabetics1 Australia 2011305050 Granted 1,491,800 Brazil BR112013006740 Granted 15,733,600 537M Canada 2811654 Granted 2,974,000 China ZL201180053583
Slide 14: PromarkerD – Route To Market
PromarkerD – Route To Market ASX: PIQ ASX:PIQ Diagnostic company / laboratory Laboratory conducts tests & submits raw Laboratory pays PIQ a royalty per license PromarkerDTM data to PromarkerD hub test Immunoassay kits PromarkerD Hub calculates ‘risk score’ manufactured and supplied and sends report
Slide 15: Diagnostics Pipeline
Diagnostics Pipeline ASX: PIQ ASX:PIQ Further Global Potential in New Markets ▪ Employs the Promarker™️ technology platform to develop novel intellectual property The Promarker™️ Research ▪ Targeting new diagnostic tests in areas of significant unmet need Pipeline & Timeline ▪ Enormous markets and r
Slide 16: In Development: Endometriosis
In Development: Endometriosis What is Endometriosis? • A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines) • The most common symptoms are chronic pain and menstrual irregularities • Diagnosis typically t
Slide 17: Timeline & Milestones
Timeline & Milestones ASX: PIQ 2021 Achievements 2022 Targets & Achievements ASX:PIQ 4 August 2021 16 Nov 2021 Major licensing deals Partnership with Royal Board 23 April 2021 for PromarkerD with 10 June 2021 Women’s Hospital & strengthened diagnostic, Proteomics International Univ. Melbourne target
Slide 18: Value Inflection Points
Value Inflection Points ASX: PIQ ASX:PIQ Exceptional Global Share Price Catalysts 2022 Opportunity Milestone Qtr Jun’22 Sep’22 Dec’22 Impact ➢ Disruptive, cutting-edge technology & proven in-house diagnostics platform PromarkerD Licensing Deals Drive global uptake and future revenue ➢ PromarkerD tes
Slide 19: Peer Comparison
Peer Comparison ASX: PIQ Market Share FY21 FY21 Net Stock Code Company Focus ASX:PIQ Capitalisation Price Revenue Profit/Loss DKD test based on AI and a combination of RENX.LSE predictive blood-based biomarkers, genetic Renalytix AI factors and electronic health records. Expensive ~A$203m 160p ~A$2.
Slide 20: Contact
Contact ASX: PIQ ASX:PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations & Corporate Advisor T:+61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T:+61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au Kyle Moss Corporate Advi
Proteomics International Laboratories — Jefferies MedTech & Biotech Virtual Summit 2022 on 6ix